Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response to influenza and pneumococcal vaccination in lenalidomide-treated multiple myeloma patients (RITUXIVAC)
2012-005713-39Phase 4Active
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jul 2014
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Prevnar 13 in multiple myeloma (MM), influenza and pneumococcal disease, sponsored by St. Antonius Ziekenhuis. Primary endpoint: Responder rate based on antibody titres to influenza vaccine and pneumococcal serotypes. Started Jul 2014; status: active.
02
Drugs
Prevnar 13
03
Conditions
multiple myeloma (MM)influenzapneumococcal disease
Beyond the preview
Go deeper on 2012-005713-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005713-39.